AR074209A1 - Derivados de pirimidina utiles para el tratamiento del cancer - Google Patents

Derivados de pirimidina utiles para el tratamiento del cancer

Info

Publication number
AR074209A1
AR074209A1 ARP090104510A ARP090104510A AR074209A1 AR 074209 A1 AR074209 A1 AR 074209A1 AR P090104510 A ARP090104510 A AR P090104510A AR P090104510 A ARP090104510 A AR P090104510A AR 074209 A1 AR074209 A1 AR 074209A1
Authority
AR
Argentina
Prior art keywords
nrere
nrcrc
nrg
membered
orc
Prior art date
Application number
ARP090104510A
Other languages
English (en)
Inventor
Ioannis Sapountzis
Heinz Stadtmueller
Bodo Betzemeier
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR074209A1 publication Critical patent/AR074209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Son apropiados para el tratamiento de enfermedades que se distinguen por una proliferacion celular excesiva o anomala, así como su utilizacion para la fabricacion de un medicamento con las propiedades mencionadas anteriormente. Reivindicacion 1: Compuestos caracterizados porque tienen la formula general (1) en donde A significa un radical, eventualmente sustituido con uno o varios R1 iguales o diferentes, seleccionados del grupo compuesto por arilo C6-15 y heteroarilo de 5-12 miembros, X es O, S o CH2; R1 significa H o un radical seleccionado del grupo compuesto por Ra, Rb y Ra sustituido con uno o varios Rc y/o Rb iguales o diferentes; R2 es un radical seleccionado del grupo compuesto por Ra y Ra sustituido con uno o multiples Rb y/o Rc iguales o diferentes; y cada Ra está seleccionado independientemente de los demás, del grupo consistente en alquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-16, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilalquilo de 4-14 miembros, heteroarilo de 5-12 miembros y heteroarilalquilo de 6-18 miembros; cada Rb es un radical apropiado y seleccionado en cada caso de forma independiente entre sí del grupo compuesto por =O, -ORc, haloalcoxi C1-3-oxi, -OCF3, =S, -SRc, =NRc, =NORc, =NNRcRc, =NN(Rg)C(O)NRcRc, -NRcRc, -ONRcRc, -N(ORc)Rc, -N(Rg)NRcRc, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Rc, -S(O)ORc, -S(O)2Rc, -S(O)2ORc, -S(O)NRcRc, -S(O)2NRcRc, -OS(O)Rc, -OS(O)2Rc, -OS(O)2ORc, -OS(O)NRcRc, -OS(O)2NRcRc, -C(O)Rc, -C(O)ORc, -C(O)SRc, -C(O)NRcRc, -C(O)N(Rg)NRcRc, -C(O)N(Rg)ORc, -C(NRg)NRcRc, -C(NOH)Rc, -C(NOH)NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)SRc, -OC(O)NRcRc, -OC(NRg)NRcRc, -SC(O)Rc, -SC(O)ORc, -SC(O)NRcRc, -SC(NRg)NRcRc, -N(Rg)C(O)Rc, -N[C(O)Rc]2, -N(ORg)C(O)Rc, -N(Rg)C(NRg)Rc, -N(Rg)N(Rg)C(O)Rc, -N[C(O)Rc]NRcRc, -N(Rg)C(S)Rc, -N(Rg)S(O)Rc, -N(Rg)S(O)ORc, -N(Rg)S(O)2Rc, -N[S(O)2Rc]2, -N(Rg)S(O)2ORc, -N(Rg)S(O)2NRcRc, -N(Rg)[S(O)2]2Rc, -N(Rg)C(O)ORc, -N(Rg)C(O)SRc, -N(Rg)C(O)NRcRc, -N(Rg)C(O)NRgNRcRc, -N(Rg)N(Rg)C(O)NRcRc, -N(Rg)C(S)NRcRc, -[N(Rg)C(O)]2Rc, -N(Rg)[C(O)]2Rc, -N{[C(O)]2Rc}2, -N(Rg)[C(O)]2ORc, -N(Rg)[C(O)]2NRcRc, -N{[C(O)]2ORc}2, -N{[C(O)]2NRcRc}2, -[N(Rg)C(O)]2ORc, -N(Rg)C(NRg)ORc, -N(Rg)C(NOH)Rc, -N(Rg)C(NRg)SRc y -N(Rg)C(NRg)NRcRc, cada Rc es, de forma independiente entre sí, H o un radical sustituido eventualmente con uno o multiples Rd y/o Re iguales o diferentes seleccionados del grupo compuesto por alquilo C1-6, cicloalquilo C3-10, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilo de 4-14 miembros, heteroarilo de 5-12 miembros y heteroaril-alquilo de 6-18 miembros, cada Rd es un radical apropiado y está seleccionado, de modo independiente entre sí, del grupo compuesto por =O, -ORe, haloalquil C1-3-oxi, -OCF3, =S, -SRe, =NRe, =NORe, =NNReRe, =NN(Rg)C(O)NReRe, -NReRe, -ONReRe, -N(Rg)NReRe, halogeno, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)Re, -S(O)ORe, -S(O)2Re, -S(O)2ORe, -S(O)NReRe, -S(O)2NReRe, -OS(O)Re, -OS(O)2Re, -OS(O)2ORe, -OS(O)NReRe, -OS(O)2NReRe, -C(O)Re, -C(O)ORe, -C(O)SRe, -C(O)NReRe, -C(O)N(Rg)NReRe, -C(O)N(Rg)ORe, -C(NRg)NReRe, -C(NOH)Re, -C(NOH)NReRe, -OC(O)Re, -OC(O)ORe, -OC(O)SRe, -OC(O)NReRe, -OC(NRg)NReRe, -SC(O)Re, -SC(O)ORe, -SC(O)NReRe, -SC(NRg)NReRe, -N(Rg)C(O)Re, -N[C(O)Re]2, -N(ORg)C(O)Re, -N(Rg)C(NRg)Re, -N(Rg)N(Rg)C(O)Re, -N[C(O)Re]NReRe, -N(Rg)C(S)Re, -N(Rg)S(O)Re, -N(Rg)S(O)ORe, -N(Rg)S(O)2Re, -N[S(O)2Re]2, -N(Rg)S(O)2ORe, -N(Rg)S(O)2NReRe, -N(Rg)[S(O)2]2Re, -N(Rg)C(O)ORe, -N(Rg)C(O)SRe, -N(Rg)C(O)NReRe, -N(Rg)C(O)NRgNReRe, -N(Rg)N(Rg)C(O)NReRe, -N(Rg)C(S)NReRe, -[N(Rg)C(O)]2Re, -N(Rg)[C(O)]2Re, -N{[C(O)]2Re}2, -N(Rg)[C(O)]2ORe, -N(Rg)[C(O)]2NReRe, -N{[C(O)]2ORe}2, -N{[C(O)]2NReRe}2, -[N(Rg)C(O)]2ORe, -N(Rg)C(NRg)ORe, -N(Rg)C(NOH)Re, -N(Rg)C(NRg)SRe y -N(Rg)C(NRg)NReRe, cada Re es, de modo independiente entre sí, H o un radical eventualmente sustituido con uno o multiples Rf y/o Rg iguales o diferentes seleccionados del grupo compuesto por alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilalquilo de 4-14 miembros, heteroarilo de 5-12 miembros o heteroarilalquilo de 6-18 miembros, cada Rf es un radical adecuado y en cada caso independientemente uno de otro, se selecciona del grupo consistente en halogeno y -CF3; y cada Rg es, independientemente entre sí, H, alquilo C1-6, cicloalquilo C3-8, cicloalquilalquilo C4-11, arilo C6-10, arilalquilo C7-16, heteroalquilo de 2-6 miembros, heterocicloalquilo de 3-8 miembros, heterocicloalquilo de 4-14 miembros, heteroarilo de 5-12 miembros o heteroarilalquilo de 6-18 miembros, eventualmente en forma de sus tautomeros, sus racematos, sus enantiomeros, sus diastereoisomeros y sus mezclas, así como eventualmente sus sales por adicion de ácidos farmacologicamente inocuos.
ARP090104510A 2008-11-24 2009-11-23 Derivados de pirimidina utiles para el tratamiento del cancer AR074209A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08169805 2008-11-24

Publications (1)

Publication Number Publication Date
AR074209A1 true AR074209A1 (es) 2010-12-29

Family

ID=40427570

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104510A AR074209A1 (es) 2008-11-24 2009-11-23 Derivados de pirimidina utiles para el tratamiento del cancer

Country Status (6)

Country Link
US (2) US20110288109A1 (es)
EP (1) EP2367799B1 (es)
AR (1) AR074209A1 (es)
ES (1) ES2690341T3 (es)
TW (1) TW201024281A (es)
WO (1) WO2010058030A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
JP5713367B2 (ja) * 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
UY33817A (es) * 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
CA2827171C (en) * 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
EP2675794B1 (en) * 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
MX353254B (es) * 2011-11-30 2018-01-05 Genentech Inc Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
CN104220428A (zh) 2012-02-03 2014-12-17 巴斯夫欧洲公司 杀真菌嘧啶化合物
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
CA2862354A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
RU2656591C2 (ru) 2013-07-11 2018-06-06 Бетта Фармасьютикалз Ко., Лтд Модуляторы протеин-тирозинкиназы и способы их применения
GB2566622B (en) * 2014-05-08 2019-07-10 Tosoh F Tech Inc 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 ５−（トリフルオロメチル）ピリミジン誘導体及びその製造法
JP6466107B2 (ja) * 2014-09-04 2019-02-06 東ソー・ファインケム株式会社 ４−フェニルチオ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
JP6479486B2 (ja) * 2015-01-16 2019-03-06 東ソー・ファインケム株式会社 ４−アルコキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
WO2020051571A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
JP2024512024A (ja) 2021-03-23 2024-03-18 ハリア・セラピューティクス・インコーポレイテッド Ｌｒｒｋ２キナーゼ阻害剤として有用なピリミジン誘導体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP2332924A1 (de) * 2001-10-17 2011-06-15 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
RS20050363A (en) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005016894A1 (en) 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
MX2007003798A (es) 2004-09-30 2007-04-23 Tibotec Pharm Ltd Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih.
JP2008526997A (ja) * 2005-01-14 2008-07-24 ニューロジェン・コーポレーション ヘテロアリール置換キノリン−４−イルアミン類縁体
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007035309A1 (en) 2005-09-15 2007-03-29 Merck & Co., Inc. Tyrosine kinase inhibitors
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7569561B2 (en) 2006-02-22 2009-08-04 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidines useful for treating cell proliferation diseases
CN101460483B (zh) 2006-03-31 2013-05-08 詹森药业有限公司 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
AU2007337088A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
AU2008210266B2 (en) 2007-01-31 2013-09-05 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
TWI484960B (zh) 2007-04-16 2015-05-21 Hutchison Medipharma Entpr Ltd 嘧啶衍生物
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders

Also Published As

Publication number Publication date
US8785464B2 (en) 2014-07-22
EP2367799A1 (en) 2011-09-28
TW201024281A (en) 2010-07-01
EP2367799B1 (en) 2018-08-01
ES2690341T3 (es) 2018-11-20
US20110288109A1 (en) 2011-11-24
US20140038993A1 (en) 2014-02-06
WO2010058030A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
AR074209A1 (es) Derivados de pirimidina utiles para el tratamiento del cancer
AR074210A1 (es) Derivados de pirimidina como inhibidores de ptk2-quinasa
AR074127A1 (es) 2,4 diaminopirimidinas y uso para la preparacion de un medicamento para el tratamiento de cancer, infecciones y enfermedades inflamatorias y autoinmunes
AR076134A1 (es) Derivados de 2,4 diaminopirimidinas
AR078513A1 (es) Pirimidinas y composiciones farmaceuticas que las comprenden
AR051743A1 (es) Tiazolil - dihidro- indazoles
AR057423A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora, preparacion farmaceutica y uso del compuesto para preparar un medicamento
AR072845A1 (es) 5-alquil-pirimidinas y su uso en el tratamiento de enfermedades mediadas por la actividad de quinasas.
AR066963A1 (es) Derivados de indolinona, preparaciones farmaceuticas que los contienen y usos de los mismos para el tratamiento y/o prevencion de cancer y enfermedades inflamatorias y autoinmunes.
AR072538A1 (es) Derivados de indolinonas, composiciones farmacéuticas y usos
AR076620A1 (es) 2,4 DIAMINOPIRIMIDINAS, COMPOSICIONES FARMACEUTICAS, PROCESOS DE PREPARACIoN Y SU USO COMO MEDICAMENTO.
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1121744T1 (el) Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων
AR073501A1 (es) Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
CU20200080A7 (es) Kit que comprende un inhibidor de lats para el suministro ocular
AR082850A1 (es) Aminopirazoloquinazolinas
CO6390110A2 (es) Compuestos y método de uso
UY35991A (es) Bencimidazol-2-aminas como inhibidores de midh1
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR070877A1 (es) Tiazolil-dihidro-indazoles, una preparacion farmaceutica en base al compuesto y uso del compuesto para preparar un medicamento
AR073700A1 (es) Heterociclos y composiciones farmaceuticas para usarse en el tratamiento de cancer, infecciones y enfermedades autoinmunitarias
PE20171238A1 (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
AR060890A1 (es) Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
CU20170085A7 (es) Derivados de imidazolidindiona para el tratamiento de la osteoartritis

Legal Events

Date Code Title Description
FB Suspension of granting procedure